ERBB2 and triple-negative breast carcinoma: At least five clinical subtypes have been identified at the molecular level: hormone receptor positive (progesterone receptor and/or estrogen receptor-positive or negative-HR+/−, i.e., luminal A and luminal B), human epidermal growth factor receptor-2 positive (HER2-positive or ERBB2+), basal-like, normal-like, and triple-negative breast cancer (TNBC) (1–3).